Table 1 Antiplatelet medications and potential pharmacogenetic genes
From: Application of personalized medicine to chronic disease: a feasibility assessment
Drug name | Brand name | Potential pharmacogenetic genes | PubMed ID | Details |
|---|---|---|---|---|
Acetylsalicylic acid | Aspirin | NTRK1; LTC4S; ITGB3 | 21390260; | Risk of ADR and lower response-associated alleles |
19862937; | ||||
12816731; | ||||
19390185 | ||||
Clopidogrel | Plavix | CYP2C19; PON1; P2RY12; ABCB1; | 22153531; | Risk or phenotype-associated alleles. Any combination of two of CYP2C19 loss-of-function alleles is associated with diminished platelet response and worse cardiovascular outcomes |
22088980; | ||||
22028352; | ||||
21881565; | ||||
21716271; | ||||
21497813; | ||||
21332306; | ||||
21170047; | ||||
20801498; | ||||
20126830; | ||||
19637098 | ||||
Prasugrel* | Effient | None | Better suited for patients who cannot metabolize clopidogrel | |
Dipyridamoles-ASA | Aggrenox |